Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · UNICHEMLAB

UNICHEM LAB

HealthcarePharmaceuticals & Biotechnology₹3401 cr market cap
₹479.20 ▲ +0.02% today As of 19 Nov 2026
52-week low ₹284.0552-week high ₹650.60

-26.4% from the 52-week high · +68.7% above the low

Unichem Laboratories Ltd. is a pharmaceutical company, which engages in the manufacturing and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 3,123 full-time employees. The firm is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. The company manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. The company has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The firm is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.

The short version. UNICHEM LAB reported revenue of ₹640 crore for Sep 2026, up 10.5% from a year earlier. Net profit was ₹22 crore. Return on equity was 9.3% in Mar 2026. Promoter holding was 70.22% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

UNICHEM LAB trades 26.4% below its 52-week high and 68.7% above its 52-week low.

Change over period: —

1M-5.0%
3M-6.6%
6M+28.4%
1Y+0.4%

2 · The business

Is it growing?

Sales, year on year+10.5%

Sep 2026 revenue of ₹640 cr.

Net margin3.5%

5.6 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue640633575521579527587533
Net profit224111264-12-105358
Net margin %3.56.61.950.7-2.1-2.09.010.9
EPS (₹)3.165.891.5537.54-1.69-1.497.528.22

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue22022111170513431270123512111180
Net profit253138-70-2023334-60-24
Net margin %11.56.5-4.1-15.12.62.8-5.0-2.0
EPS (₹)35.9119.53-10.01-28.724.74.88-8.55-3.38

3 · The quality

How well does it turn capital into profit?

Return on equity was 9.3% in Mar 2026; debt to equity is 0.17.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %9.35.6-3.0-8.3
Return on capital %11.46.8-1.6-6.2
EBITDA margin %19.814.04.3-3.3
Net margin %11.26.4-4.1-14.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR17.9%12.0%
Profit CAGR—49.1%
Debt to equity0.17
Interest cover10.3x
Current ratio2.48
P/E ratio9.8

4 · The owners

Who holds it, and are they adding?

Promoter holding70.22%

Unchanged over 8 quarters.

Foreign institutions2.7%

Up 1.64 pts over 8 quarters.

Domestic institutions9.4%

Down 2.23 pts over 8 quarters.

Mutual fund schemes4

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter70.2270.2270.2270.2270.2270.2270.2270.220.0
FII1.060.980.981.00.991.00.92.7+1.64
DII11.6311.3210.9210.7510.7410.6310.469.4-2.23
Public17.0917.4817.8818.0318.0518.1518.4217.68+0.59

Mutual fund holdings · Oct 2026

4 schemes hold this stock

4 the month before.

  • DSP Healthcare Fund1.47% of NAV
  • HDFC Small Cap Fund0.62% of NAV
  • Motilal Oswal BSE Healthcare ETF0.06% of NAV
  • Bandhan BSE Healthcare Index Fund0.06% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for UNICHEM LAB are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about UNICHEM LAB

What is the UNICHEM LAB share price?

UNICHEM LAB (UNICHEMLAB) last closed at ₹479.20, up 0.02% on the day. Its 52-week range is ₹284.05 to ₹650.60.

What is the market cap of UNICHEM LAB?

UNICHEM LAB has a market capitalisation of about ₹3,401 crore. Its price-to-earnings ratio is 9.8.

How are UNICHEM LAB's latest results?

UNICHEM LAB reported revenue of ₹640 crore for Sep 2026, up 10.5% from a year earlier. Net profit was ₹22 crore. Return on equity was 9.3% in Mar 2026. Promoter holding was 70.22% in Sep 2026, up 0.00 points over 8 quarters.

Who owns UNICHEM LAB?

As of Sep 2026, shareholding was: Promoter 70.22%, FII 2.7%, DII 9.4%, Public 17.68%.

How many mutual funds hold UNICHEM LAB?

4 mutual fund schemes held UNICHEM LAB in October 2026. That compares with 4 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 01 Aug 2022 · Final Dividend - Rs. 4
  • 22 Jul 2021 · Final Dividend - Rs. 4
  • 20 Aug 2020 · Dividend - Rs. 4
  • 18 Jul 2019 · Dividend - Rs. 4
  • 19 Jul 2018 · Dividend - Rs. 5
  • 13 Jul 2017 · Final Dividend - Rs. 3

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.